1. Home
  2. ATXG vs ONCO Comparison

ATXG vs ONCO Comparison

Compare ATXG & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATXG

Addentax Group Corp.

HOLD

Current Price

$0.40

Market Cap

4.6M

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$1.70

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATXG
ONCO
Founded
2014
2018
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ATXG
ONCO
Price
$0.40
$1.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.8K
60.7K
Earning Date
02-13-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,141,952.00
$1,223,751.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$1.37
52 Week High
$1.86
$88.40

Technical Indicators

Market Signals
Indicator
ATXG
ONCO
Relative Strength Index (RSI) 44.40 40.50
Support Level $0.38 $1.52
Resistance Level $0.42 $1.88
Average True Range (ATR) 0.04 0.15
MACD 0.00 0.05
Stochastic Oscillator 55.68 61.11

Price Performance

Historical Comparison
ATXG
ONCO

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: